Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials
Barcelona, Spain (ots/PRNewswire) - - New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity - Results suggest less frequent, every four week dosing of lebrikizumab provided ...
mehr